Recombinant Proteins Market Report 2026

Recombinant Proteins Market Overview

• Recombinant Proteins market size has reached to $2.55 billion in 2025 • Expected to grow to $4.84 billion in 2030 at a compound annual growth rate (CAGR) of 13.7% • Growth Driver: The Impact of Personalized Medicine on the Growth of the Recombinant Protein Market • Market Trend: Strategic Collaborations Driving Innovation And Market Competitiveness In Recombinant Protein Industry • North America was the largest region in 2025.

What Is Covered Under Recombinant Proteins Market?

Recombinant proteins refer to modified or edited proteins encoded by recombinant DNA, made up of a plasmid in which the gene of an interest target protein is cloned downstream of a promoter region. They are used to make pharmaceuticals, protein-based polymers for drug delivery, antibodies and enzymes for disease treatment, protein scaffolds for tissue engineering, and a variety of other things. The main types of recombinant protein products are antibodies, cytokines, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and others. Antibodies refer to a protein immune system component that travels through the blood, detects foreign objects like bacteria and viruses, and destroys them. They are used in various applications such as drug and discovery development, therapeutics, research, and others. It is used mostly by pharmaceutical and biotechnology companies, academic and research institutes, diagnostic laboratories, and others.

What Is The Recombinant Proteins Market Growth Forecast?

The recombinant proteins market size is expected to see rapid growth in the next few years. It will grow to $4.84 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing adoption of next-generation biologics, rising investments in biomanufacturing facilities, growing demand for personalized therapeutics, expansion of biosimilar development, increasing use of recombinant proteins in research. Major trends in the forecast period include increasing production of therapeutic antibodies, rising demand for recombinant enzymes, growing use of protein engineering techniques, expansion of biologics manufacturing capacity, enhanced focus on high-purity protein expression.

Global Recombinant Proteins Market Segmentation

1) By Product: Antibodies, Cytokines, Virus Antigens, Enzymes, Recombinant Regulatory Proteins, Hormones, Other Products 2) By Application: Drug And Discovery Development, Therapeutics, Research, Other Applications 3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Diagnostic Laboratories, Other End Users Subsegments: 1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies 2) By Cytokines: Interleukins, Interferons, Tumor Necrosis Factors (TNFs) 3) By Virus Antigens: Viral Capsid Proteins, Envelope Proteins 4) By Enzymes: Restriction Enzymes, Polymerases, Ligases 5) By Recombinant Regulatory Proteins: Transcription Factors, Receptors 6) By Hormones: Insulin, Growth Hormones 7) By Other Products: Fusion Proteins, Peptide Therapeutics

What Is The Driver Of The Recombinant Proteins Market?

The growing focus on personalized medicine is expected to propel the growth of the recombinant protein market going forward. Personalized medicine refers to a medical approach that tailors’ treatments and therapies to the individual characteristics, genetics, and needs of each patient, with the goal of achieving more effective and targeted healthcare outcomes. The growth in personalized medicine is attributed to advancements in genomic technologies and data analytics, enabling tailored treatments based on individual genetic profiles. Recombinant proteins enable personalized medicine by allowing the development of customized therapies that target an individual’s unique genetic and molecular profile, improving treatment effectiveness and reducing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from the 6 approved in 2022. Therefore, the growing focus on personalized medicine is driving the growth of the recombinant protein industry going forward.

Key Players In The Global Recombinant Proteins Market

Major companies operating in the recombinant proteins market are Abcam plc, Abnova Corporation, Bio-Rad Laboratories Inc., Merck Co. & KGaA, R&D Systems Inc., Proteintech Group Inc., RayBiotech Life Inc., GenScript Biotech Corporation, Elpiscience Biopharmaceuticals Co. Ltd., Elevian Inc., Gigagen Inc., Janssen- Cilag Pvt. Ltd., Sino Biological Inc., OriGene Technologies Inc., Feldan Therapeutics Inc., Bio-Techne Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Crown Bioscience Inc., Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Eli Lilly and Company

Global Recombinant Proteins Market Trends and Insights

Major companies operating in the recombinant protein market are undergoing partnerships to gain a competitive edge in the market. Partnerships often foster innovation by combining the expertise of different entities. For instance, in October 2023, ARTES Biotechnology GmbH, a Germany-based biotechnology company collaborated with Basic Pharma, a Netherlands-based pharmaceutical company. The collaboration involves a strategic partnership and co-marketing agreement aimed at developing and producing non-GMP recombinant proteins, with a focus on establishing a streamlined supply chain process to expedite the time-to-market for new pharmaceutical products.

What Are Latest Mergers And Acquisitions In The Recombinant Proteins Market?

In May 2024, Sanofi, a France-based global healthcare company engaged in developing innovative pharmaceuticals, biologics, and rare disease therapies, acquired Inhibrx, Inc. for approximately $1.7 billion plus a contingent value right. With this acquisition, Sanofi gains access to SAR447537, a differentiated human recombinant protein therapeutic targeting alpha-1 antitrypsin deficiency (AATD), thereby strengthening its recombinant protein portfolio and expanding its rare disease capabilities while improving pipeline depth and biologics innovation. Inhibrx, Inc. is a US-based biopharmaceutical company that develops recombinant protein therapeutics and engineered biologics for rare diseases and oncology.

Regional Outlook

North America was the largest region in the recombinant protein market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Recombinant Proteins Market?

The recombinant protein market consists of sales of recombinant monoclonal antibodies, interferons, and interleukins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.